NASDAQ:INFI - Infinity Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.40 +0.09 (+3.90 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$2.40
Today's Range$2.2501 - $2.40
52-Week Range$1.10 - $3.75
Volume247,663 shs
Average Volume350,814 shs
Market Capitalization$131.32 million
P/E Ratio-2.89
Dividend YieldN/A
Beta2.24
Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreement with Arcus Biosciences, Inc. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio8.89
Quick Ratio8.89

Price-To-Earnings

Trailing P/E Ratio-2.89
Forward P/E Ratio-5.22
P/E GrowthN/A

Sales & Book Value

Annual Sales$6 million
Price / Sales22.74
Cash FlowN/A
Price / CashN/A
Book Value$0.94 per share
Price / Book2.55

Profitability

EPS (Most Recent Fiscal Year)($0.83)
Net Income$-41,830,000.00
Net MarginsN/A
Return on Equity-64.18%
Return on Assets-54.82%

Miscellaneous

Employees22
Outstanding Shares56,850,000
Market Cap$131.32 million

Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.08. View Infinity Pharmaceuticals' Earnings History.

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Infinity Pharmaceuticals.

What price target have analysts set for INFI?

2 brokers have issued 12 month price targets for Infinity Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect Infinity Pharmaceuticals' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.

What is the consensus analysts' recommendation for Infinity Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Infinity Pharmaceuticals.

Are investors shorting Infinity Pharmaceuticals?

Infinity Pharmaceuticals saw a drop in short interest in August. As of August 15th, there was short interest totalling 1,220,490 shares, a drop of 28.5% from the July 31st total of 1,705,915 shares. Based on an average daily volume of 389,249 shares, the short-interest ratio is presently 3.1 days. Currently, 2.2% of the shares of the company are short sold. View Infinity Pharmaceuticals' Current Options Chain.

Who are some of Infinity Pharmaceuticals' key competitors?

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 58)
  • Dr. Lawrence E. Bloch, Pres & Treasurer (Age 52)
  • Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 51)
  • Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 39)
  • Ms. Melissa Hackel, VP of Fin.

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Platinum Investment Management Ltd. (1.99%), Dimensional Fund Advisors LP (1.66%), Acadian Asset Management LLC (0.66%), Essex Investment Management Co. LLC (0.29%) and Algert Global LLC (0.13%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok, Lawrence E Bloch, Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

Which institutional investors are selling Infinity Pharmaceuticals stock?

INFI stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd.. Company insiders that have sold Infinity Pharmaceuticals company stock in the last year include Adelene Q Perkins and Jeffery Kutok. View Insider Buying and Selling for Infinity Pharmaceuticals.

Which institutional investors are buying Infinity Pharmaceuticals stock?

INFI stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Acadian Asset Management LLC, Essex Investment Management Co. LLC and Algert Global LLC. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $2.40.

How big of a company is Infinity Pharmaceuticals?

Infinity Pharmaceuticals has a market capitalization of $131.32 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe.

What is Infinity Pharmaceuticals' official website?

The official website for Infinity Pharmaceuticals is http://www.infi.com.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]


MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  585
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2018 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel